Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.

Abstract: The present invention provides a method of identifying a subject as having an increased risk of sudden cardiac death or cardiac arrhythmia by detecting in the subject the presence of various polymorphisms associated with an increased risk of sudden cardiac death or cardiac arrhythmia.

Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.

Abstract: The present invention provides a method of identifying a subject as having an increased risk of sudden cardiac death or cardiac arrhythmia by detecting in the subject the presence of various polymorphisms associated with an increased risk of sudden cardiac death or cardiac arrhythmia.

Abstract: Disclosed is a method of treating a non-cardiovascular disorder characterized by an abnormal persistent sodium current in a subject in need of treatment thereof, said method comprising administering to the subject an effective amount of a compound of Formula (I): wherein: m is 1 or 2; R1, R2, R3, R4, and R5 are each independently selected from the group consisting of hydrogen, halo, CF3, CN, OR22, SR22, N(R22)2, S(=O)R22, SO2N(R22)2, C(?O)R22, alkylamido, alkyl, alkenyl, morpholino, and pyrrolyl, wherein the alkyl substituent is optionally substituted with one substituent selected from the group consisting of OR22, or R2 and R3 together or R4 and R5 together can be alkylene; R6, R7, and R8 are each independently selected from the group consisting of H and alkyl; R9, R10, R11, R12, R13, R14, R15, and R16 are each independently selected from the group consisting of H and alkyl, or wherein one or more of R9 and R10, R11 and R12, R13 and R14, and R15 and R16 are together ?O; R17, R18, R19, R20 and R21 are eac